Pharma BD Deal Intelligence
A $21B acquisition that gave AbbVie full ownership of Imbruvica, the first-in-class BTK inhibitor that peaked at $5.4B in annual sales across CLL, MCL, and WM. The deal diversified AbbVie beyond Humira at a critical moment, though ibrutinib revenue has since declined under competitive pressure.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
AbbVie to Acquire Pharmacyclics, including its blockbuster product Imbruvica, Creating an Industry Leading Hematological Oncology Franchise. Under the terms of…
AbbVie Acquires Oncology Drug Firm Pharmacyclics for $21 Billion.
Imbruvica projected at $14B peak sales with 85% reduction in death risk in CLL trials. Whether it offsets Humira risk still remains to be seen.
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
AbbVie acquired Pharmacyclics for approximately $21 billion ($261.25 per share in a 58% cash / 42% stock mix), gaining full ownership of Imbruvica (ibrutinib), a first-in-class BTK inhibitor with four approved indications in hematologic malignancies and over 50 ongoing clinical studies.
Assessment window: 10yr post-close.
20K US cases/yr · $6.5B Global CLL Market (2015) · $3.5B Imbruvica Peak Revenue (2020)
CLL is the most common adult leukemia in the West. Ibrutinib (Imbruvica) was the first BTK inhibitor, enabling oral, continuous therapy that achieved deep remissions without chemotherapy.
Imbruvica peaked at $5.4B globally (AbbVie + J&J). Next-gen BTK inhibitors (acalabrutinib, zanubrutinib) have since eroded share significantly.
4K US cases/yr · $1.2B Global MCL Market (2015) · ~50% 5-Year MCL Survival Rate
MCL is an aggressive B-cell lymphoma (~6% of NHL). Imbruvica received breakthrough therapy designation for MCL, providing a new option for relapsed/refractory patients.
Imbruvica competed with lenalidomide and bortezomib in later lines. CAR-T therapies (Tecartus) later offered alternatives for relapsed MCL.
AbbVie agrees to acquire Pharmacyclics for $261.25/share in cash and stock (~$21B), targeting full ownership of Imbruvica (ibrutinib), a first-in-class BTK inhibitor for blood cancers.
AbbVie subsidiary commences exchange offer for all outstanding Pharmacyclics shares at $261.25/share in a mix of cash and AbbVie stock.
The exchange offer for Pharmacyclics common stock expires at 5:00 PM New York time on May 22, 2015, with sufficient shares tendered to complete the acquisition.
AbbVie completes acquisition of Pharmacyclics via short-form merger under Delaware 251(h), gaining full ownership of Imbruvica with ~$1B in existing 2015 run-rate sales.
Full-year 2017 global Imbruvica net revenues reach $2.573B, more than doubling from acquisition-year levels as label expansions in CLL, WM, and MZL drive uptake.
Global Imbruvica net revenues grow to $3.59B in 2018, on track for the $5B peak revenue target AbbVie projected at acquisition.
AbbVie paid $21B for Pharmacyclics and Imbruvica grew from ~$1B to $5.3B peak revenue (2020), a 5x return on the lead asset alone. The BTK inhibitor defined a treatment class. However, Imbruvica now faces competition from next-gen BTK inhibitors (acalabrutinib, zanubrutinib) and revenue has begun declining from peak. Net: exceptional value creation over a 5-year window.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AbbVie Inc. / Pharmacyclics Inc. (this deal) | 2015 | $21.0B | 79 |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| AbbVie Inc. / Genmab A/S | 2020 | $3.9B | 81 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
| AbbVie Inc. / ImmunoGen Inc. | 2023 | $10.1B | 69 |
| AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. | 2024 | $2.0B | 64 |
| AbbVie Inc. / MedinCell S.A. | 2024 | $1.9B | 61 |
← Browse all deals · How we score deals
More: 2015 deals · AbbVie Inc. deals · Hematology deals